Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: A retrospective analysis of four clinical studies and two observational cohorts

HIV Clinical Trials

Volumn 3, Issue 4, 2002, Pages 316-323

  Clotet, Bonaventura ^a   Ruiz, Lidia ^a   Martinez Picado, Javier ^a   Negredo, Eugènia ^a   Hill, Andrew ^a   Popescu, Matei ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

HAART; Nelfinavir; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; FEASIBILITY STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIROLOGY; VIRUS ISOLATION; WILD TYPE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; GENETICS; MUTATION; VIRUS GENE; VIRUS GENOME;

CLINICAL TRIALS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; GENES, VIRAL; GENOME, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; NELFINAVIR; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0035986086     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/67te-gpxq-r1lb-bpkg     Document Type: Article

References (29)

1. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
2. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
3. Evaluation of D30N and L90M resistance profiles in patients treated with nelfinavir alone or in combination therapy
4. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
5. Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors
6. Evolution of IAS-USA primary protease resistance mutations during protease inhibitor salvage therapy
7. Virologic responses to a ritonavir-saquinavir-containing regiman in patients who had previously failed nelfinavir
8. The efficacy of ritonavir (RTV)/saquinavir (SQV) antiretroviral therapy (ART) in patients who failed nelfinavir (NFV): A multi-center clinical cohort study
9. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
10. Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene
11. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
12. Evidence of a mutually exclusive relationship between the HIV-1 protease inhibitor resistance mutations D30N and L90M
13. ViroLogic Clinical Reference Laboratory. Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 mutations at positions 46 and 54
14. Virologic response to indinavir (IDV), efavirenz (EFV) and adefovir (ADV) among patients failing nelfinavir (NFV)
15. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
16. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
17. HIV-1 reverse transcriptase (RT) genotypes from patients receiving abacavir/efavirenz/amprenavir ± other antiretroviral therapy (ART): A 48-week follow-up
18. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
19. AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients
20. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virological evaluation of the AVANTI 2 and AVANTI 3 studies
21. Comparison of the emergence of genotypic resistance over 60 weeks of therapy with Iopinavir/ritonavir (Kaletra™) or nelfinavir plus d4T/3TC
22. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection
23. Protease genotype and virologic failure in nucleoside-experienced subjects treated with two NRTIs, nelfinavir (NFV) and/or efavirenz (EFV) in ACTG 364
24. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir
25. Assessment of virological failures in HIV-1 infected patients initiating a first-line PI-containing regimen (APROCO-ANRS EP11 study)
26. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
27. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
28. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir